Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

HopeMed of China In-Licenses Hair Loss/Endometriosis Treatment from Bayer

publication date: Apr 8, 2019

Hope Medicine, a China startup, acquired a global license from Bayer AG to develop and commercialize a mAb targeting the PRL receptor as a treatment for male and female pattern hair loss, endometriosis and other chronic diseases with dysregulated PRL signaling. HopeMed was spun out of the lab of Professor Rui-Ping Xiao at the Institute of Molecular Medicine at Peking University. Bayer and IMM collaborated to discover the candidate. HopeMed concurrently completed a Series A funding from Trustbridge Partners and Qi Rui You Kang, a China PE firm. More details....

Stock Symbol: (F: BAYN)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here